Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates
Year: 2022
Type: article
Source: Blood Advances
Authors: Antoine N. Saliba, Scott H. Kaufmann, Eytan M. Stein, Prapti A. Patel, Maria R. Baer, Wendy Stock, Michael Deininger, William Blum, Gary J. Schiller, Rebecca L. Olin, Mark R. Litzow, Tara L. Lin, Brian J. Ball, Michael M. Boyiadzis, Elie Traer, Olatoyosi Odenike, Martha L. Arellano, Alison Walker, Vu H. Duong, Tibor Kovacsovics, Robert H. Collins, Abigail B. Shoben, Nyla A. Heerema, Matthew C. Foster, Kevin L. Peterson, Paula A. Schneider, Molly Martycz, Theophilus J. Gana, Leonard Rosenberg, Sonja Marcus, Ashley O. Yocum, Timothy Chen, Mona Stefanos, Alice S. Mims, Uma Borate, Amy Burd, Brian J. Druker, Ross L. Levine, John C. Byrd, James M. Foran
Institutions: Mayo Clinic, Memorial Sloan Kettering Cancer Center, The University of Texas Southwestern Medical Center, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Chicago, University of Utah, Huntsman Cancer Institute, Emory University, Winship Cancer Institute, University of California, Los Angeles, University of California, San Francisco, University of Kansas Medical Center, City Of Hope National Medical Center, University of Pittsburgh, UPMC Hillman Cancer Center, Oregon Health & Science University, Moffitt Cancer Center, The Ohio State University, University of Maryland, Baltimore, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Blood Cancer United, University of Cincinnati, Mayo Clinic in Florida, Mayo Clinic Comprehensive Cancer Center (Florida)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
OpenAlex ID: W4307778261